/AMGN
Amgen Inc.
AMGN • NASDAQAMGN • NASDAQ • Healthcare
$367.79-2.61%-9.85
$367.79-2.61%(-9.85)Healthcare
GoAI Score
Sign in to unlock
Valuation
50Fair Value
Sentiment
39Bearish
Risk
100Low Risk
Momentum
79Positive
Institutional-Grade Intelligence
🏆PRO
Actionable Intelligence
AI-driven stance, execution logic & risk thresholds
Catalyst Roadmap
Event timeline with expected impact & market context
Deep Insights
Fact-checked analysis & score logic breakdown
Financial Statements
Margin Trends
Gross
70.8%▲9.3pp
Revenue after COGS
Operating
29.1%▲7.3pp
After operating expenses
Net
21.0%▲8.8pp
Bottom-line profitability
Gross Margin
Operating Margin
Net Margin
Valuation Snapshot
P/E Ratio
22.8
Price vs earnings
EV/EBITDA
14.0
Enterprise value
FCF Yield
4.6%
Cash generation
Earnings Yield
4.4%
Inverse of P/E
Capital Efficiency
35
GoAI Quality ScoreExcellent
ROEReturn on Equity
89.1%Strong
ROAReturn on Assets
8.5%Strong
ROICReturn on Invested Capital
13.2%Strong
Financial Health
Current RatioAdequate
1.14
Short-term solvency (>1.5)
Net Debt / EBITDAManageable
2.87x
Debt repayment capacity (<3x)
Income QualityStrong
1.29
Cash backs earnings (>1)
Revenue & Profitability
Revenue
Net Income
Net Loss
Income Statement
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $36.74B | $33.42B | $28.19B | $26.32B | $25.98B |
| Gross Profit | $26.01B | $20.57B | $19.77B | $19.92B | $19.52B |
| Gross Margin | 70.8% | 61.5% | 70.1% | 75.7% | 75.2% |
| Operating Income | $10.68B | $7.26B | $7.90B | $9.57B | $7.64B |
| Net Income | $7.71B | $4.09B | $6.72B | $6.55B | $5.89B |
| Net Margin | 21.0% | 12.2% | 23.8% | 24.9% | 22.7% |
| EPS | $14.33 | $7.62 | $12.56 | $12.18 | $10.34 |
Average Price Target
$347.73▼ 5.5% Downside
Past 12 Months
12 Month Forecast
Based on 50 Wall Street analysts offering 12 month price targets for Amgen Inc., the average price target is $347.73, with a high forecast of $432.00 and a low forecast of $185.00. The average price target represents a 5.5% decrease from the current price of $367.79.
Highest
$432.00
Average
$347.73
Lowest
$185.00
Rating Distribution
Strong Buy
0
0%
Buy
22
59%
Hold
12
32%
Sell
3
8%
Strong Sell
0
0%
Recent Analyst Ratings
FirmActionRatingDate
Wells Fargo● Maintain
Equal Weight
2026-02-19Piper Sandler● Maintain
Overweight
2026-02-18Argus Research● Maintain
Buy
2026-02-06Guggenheim● Maintain
Neutral
2026-02-06Morgan Stanley● Maintain
Equal Weight
2026-02-04Citigroup● Maintain
Neutral
2026-02-04Leerink Partners● Maintain
Outperform
2026-02-04Cantor Fitzgerald● Maintain
Neutral
2026-02-04UBS● Maintain
Buy
2026-01-26Bernstein▼ Downgrade
Outperform→Market Perform
2026-01-20Earnings History & Surprises
BEAT RATE
94%
Last 18 quarters
AVG SURPRISE
+7.0%
EPS vs Estimate
BEATS / MISSES
17/1
Last 18 quarters
LATEST EPS
$5.29
Q1 '26
QUARTERLY EPS TREND
Estimated
Beat
Miss
QUARTERLY DETAIL
Q1 '26
+11.8%
$5.29 vs $4.73
Q4 '25
+12.4%
$5.64 vs $5.02
Q3 '25
+14.0%
$6.02 vs $5.28
Q2 '25
+14.8%
$4.90 vs $4.27
Q1 '25
+5.4%
$5.31 vs $5.04
Q4 '24
+9.2%
$5.58 vs $5.11
Q3 '24
-0.2%
$4.97 vs $4.98
Q2 '24
+2.1%
$3.96 vs $3.88
Q1 '24
+2.6%
$4.71 vs $4.59
Q4 '23
+6.7%
$4.96 vs $4.65
Q3 '23
+12.6%
$5.00 vs $4.44
Q2 '23
+3.4%
$3.98 vs $3.85
No investor questions available.
Latest News
No news available